Stage (next event)
Phase 1 (Preliminary safety and immunogenicity results)
Q4 2020 (Est)
Catalyst Info & Data Links
TITLE: COVID-19 Vaccine DVAX and Clover Phase 1 (Preliminary safety and immunogenicity results)
WHAT IS THE CATALYST EVENT?
Phase I (Preliminary safety and immunogenicity results)
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q4 2020 (Est)
11-004-2020 Quarterly Slide (Slide 14)
MECHANISM OF ACTION
SCB-2019 is a recombinant subunit vaccine candidate for COVID-19. Utilizing our patented Trimer-Tag© technology, Clover has produced a S-Trimer subunit vaccine candidate that resembles the native trimeric viral spike via mammalian cell-culture production system.
Adjuvant CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell memory responses. Additionally, CpG 1018 strongly favors development of the Th1 subset of helper T cells, the type of helper T cell that is essential for protection from infections with viruses and intracellular bacteria. CpG 1018 targets a single, well defined receptor (TLR9) expressed on only a few key cell types and the mechanisms of action as an adjuvant are quite well understood. CpG 1018 provides a well‑developed technology and a significant safety database, potentially accelerating the development of novel vaccines.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post